Market Size of HbA1c Testing Industry
| Study Period | 2018-2029 |
| Market Size (2024) | USD 1 Billion |
| Market Size (2029) | USD 1 Billion |
| CAGR (2024 - 2029) | 1.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
HbA1c Testing Market Analysis
The HbA1c Testing Market size is estimated at USD 1 billion in 2024, and is expected to reach USD 1 billion by 2029, growing at a CAGR of 1% during the forecast period (2024-2029).
People with diabetes mellitus had a greater risk of contracting COVID-19 infection. Various studies suggested that type-2 diabetes mellitus patients had increased chances of pulmonary damage following SARS-COV-2 infection. The hyperglycemic state was an important prognostic factor in diabetic patients exposed to SARS-CoV-2. HbA1c was the only predictor of COVID‐19 hospitalization among other chronic health conditions, and the risk for hospitalization increased at HbA1c ≥ 8%, which suggested its pathogenic importance and clinical utility. Therefore, the urgent need to control elevated blood glucose control gave a boost to the market during the pandemic.
HbA1c is measured to determine the three-month average blood sugar level and can be used as a diagnostic test for diabetes mellitus. It is also an assessment test for glycemic control in people with diabetes. The test is limited to a three-month average because the average lifespan of a red blood cell is four months. In diabetes, higher amounts of glycated hemoglobin indicate poorer control of blood glucose levels and have been associated with cardiovascular disease, nephropathy, neuropathy, and retinopathy.
The HbA1c Test is an accurate and easy-to-administer test and can be an effective tool in the diagnosis of diabetes. A combination of the Fasting glucose test and HbA1c test enhances the diagnostic accuracy of individual tests. The HbA1c test helps in glycemic control and predicts the lipid profile in diabetic patients. Due to increasing diabetes prevalence worldwide, the HbA1c test market is expected to continuously grow as part of the diagnostic and prognostic tool, leading to better patient care and clinical outcomes.
Furthermore, Government initiatives such as the roll-out of the world’s first program to transform diabetes care for people under 40 in August 2023 by NHS, in which around 140,000 people aged 18 to 39 years old will likely receive additional tailored health checks from healthcare staff, and support with diabetes management, such as blood sugar level control, weight management, and cardiovascular risk minimization are likely to facilitate the market growth over the forecast period. The NHS is the first health system in the world to put in place a national, targeted program for high-risk groups of people.
